Dose related pharmacokinetics of ofloxacin in healthy volunteers

Immanuel, Chandra and Hemanth Kumar, A K and Gurumurthy, P and Venkatesan, P (2002) Dose related pharmacokinetics of ofloxacin in healthy volunteers. International Journal of Tuberculosis and Lung Disease, 6 (11). pp. 1017-1022. ISSN Print: 1027-3719; Online: 1815-7920

[thumbnail of 200211.pdf]
200211.pdf - Published Version

Download (108kB)


OBJECTIVE: To evaluate the pharmacokinetic profile of ofloxacin in healthy volunteers after single oral doses of 600 and 800 mg. DESIGN: Seven healthy volunteers were administered 600 and 800 mg of ofloxacin on two occasions with an interval of one week. Paired samples of blood and saliva were collected after 1, 2, 3, 6, 9, 12, 24, 32 and 48 hours post-dose. Urine samples were collected over a period of 0–6, 6–12 and 12–24 hours. Concentrations of ofloxacin in plasma, saliva and urine were assayed by high performance liquid chromatography. RESULTS: Increases of 22% in peak plasma concentration (Cmax) and 40% in area under the concentrationtime curve (AUC0–24) were observed with the 800 mg dose. The other parameters, namely time to attain Cmax, half-life, the apparent volume of distribution, plasma and renal clearance and percentage of dose excreted in urine over 24 hours were independent of doses. The mean ratios of the concentration in saliva to the concentration in plasma ranged from 0.4–0.6, and the correlation coefficient was 0.94. CONCLUSIONS: Dose proportionality was observed in Cmax and AUC0–24 when 600 and 800 mg doses of ofloxacin were given. Ofloxacin determined in saliva seems to be suitable for therapeutic drug monitoring.

Item Type: Article
Uncontrolled Keywords: pharmacokinetics; saliva to serum concentration ratio; urinary excretion; ofloxacin; tuberculosis
Subjects: Tuberculosis > Laboratory Research > Biochemical
Divisions: Basic Science Research > Biochemistry
Depositing User: Dr. Rathinasabapati R
Date Deposited: 08 Nov 2013 06:32
Last Modified: 10 Mar 2016 04:34

Actions (login required)

View Item View Item